NO990721L - Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser - Google Patents

Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser

Info

Publication number
NO990721L
NO990721L NO990721A NO990721A NO990721L NO 990721 L NO990721 L NO 990721L NO 990721 A NO990721 A NO 990721A NO 990721 A NO990721 A NO 990721A NO 990721 L NO990721 L NO 990721L
Authority
NO
Norway
Prior art keywords
crystalline form
butanoyl
piperidin
ethylglycyl
compounds
Prior art date
Application number
NO990721A
Other languages
English (en)
Other versions
NO990721D0 (no
Inventor
Zofia J Chrzan
James J Mencel
David Toledo-Velasquez
Vincent Windisch
Rick G Woodward
Diane C Salazar
Narasimha M Vemuri
Anthony J Gardetto
Matthew R Powers
Gregory G Kubiak
Robert C Liu
Benoit J Vanasse
James P Sherbine
Walter Rodriguez
Adam W Sledeski
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of NO990721D0 publication Critical patent/NO990721D0/no
Publication of NO990721L publication Critical patent/NO990721L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Oppfinnelsen rettes mot en ikke-hygroskopisk stabil krystallinsk form av den anti-trombotiske forbin-delsen N- [N-[N-(4-piperidin-4-yl)butanoyl)-N-etyl-glysyl]-(L)-aspartyl]-(L)-p-cykloheksylalanin-amid, fremgangsmåter ved fremstillingen av den stabile krystallinske formen, en farmasøytisk sammensetning derav og intermediater derav, og oppfinnelsen rettes også mot fremgangsmåter ved fremstilling av en forbindelse med formel (II), hvor: A, B, Z,,, G, R, m, n og p er som definert heri.
NO990721A 1996-08-21 1999-02-16 Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser NO990721L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2428496P 1996-08-21 1996-08-21
PCT/US1997/014756 WO1998007696A1 (en) 1996-08-21 1997-08-21 Stable non-hygroscopic crystalline form of n-[n-n-(4-(piperidin-4-yl)butanoyl)-n-ethylglycyl] compounds

Publications (2)

Publication Number Publication Date
NO990721D0 NO990721D0 (no) 1999-02-16
NO990721L true NO990721L (no) 1999-04-20

Family

ID=21819807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990721A NO990721L (no) 1996-08-21 1999-02-16 Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser

Country Status (20)

Country Link
US (2) US6153588A (no)
EP (1) EP0923553B1 (no)
JP (1) JP4008499B2 (no)
KR (1) KR20000068229A (no)
CN (2) CN1491942A (no)
AP (1) AP9901462A0 (no)
AT (1) ATE390438T1 (no)
AU (1) AU733591B2 (no)
BG (1) BG63538B1 (no)
BR (1) BR9711340A (no)
CA (1) CA2263647C (no)
DE (1) DE69738601T2 (no)
EA (1) EA001362B1 (no)
IL (1) IL128561A0 (no)
NO (1) NO990721L (no)
OA (1) OA10979A (no)
PL (1) PL331772A1 (no)
SK (1) SK21999A3 (no)
WO (1) WO1998007696A1 (no)
ZA (1) ZA977510B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL331772A1 (en) * 1996-08-21 1999-08-02 Rhone Poulenc Rorer Pharma Stable non-hygroscopic crystalline form of n-[n-n-(4-piperidin-4-yl)-n-ethylglycin] compounds
WO1999019294A1 (en) * 1997-05-14 1999-04-22 Aventis Pharmaceuticals Products Inc. Legal/Patents Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
EA002724B1 (ru) * 1997-10-10 2002-08-29 Авентис Фармасьютикалз Продактс Инк. Способ получения азациклоалкилалканоилпсевдотетрапептидов
WO2000040601A1 (en) * 1998-12-30 2000-07-13 Aventis Pharmaceuticals Products Inc. Process for preparing a stable non-hygroscopic crystalline n-[n-[n- piperdin- 4-yl)butanoyl)- n.ethylglycyl]- (l)-aspartyl] -ss-cyclohexylalanine amide
US20050238834A1 (en) * 2004-04-21 2005-10-27 Eastman Kodak Company High modulus label with compliant carrier sheet
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US9704557B2 (en) * 2013-09-25 2017-07-11 Qualcomm Incorporated Method and apparatus for storing retention time profile information based on retention time and temperature
CN108697770B (zh) 2015-12-21 2023-08-01 得克萨斯技术大学联合体 用于溶液相gap肽合成的系统和方法
WO2019217116A1 (en) * 2018-05-06 2019-11-14 Gap Peptides Llc Method for solution-phase peptide synthesis
WO2020159837A1 (en) 2019-02-01 2020-08-06 Gap Peptides Llc Synthesis strategy for gap protecting group
US12024537B2 (en) 2018-05-31 2024-07-02 Sederma Compositions and methods for chemical synthesis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
US5264420A (en) 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5218138A (en) 1992-09-02 1993-06-08 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2166075A1 (en) * 1993-06-30 1995-01-12 Yoshiharu Ikeda Novel dipiperidine derivative
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
UA44258C2 (uk) * 1993-10-15 2002-02-15 Рон-Пуленк Рорер Фармасьютікалз Інк. Антитромботичні азациклоалкілалканоілпептиди та псевдопептиди, фармацевтична композиція, що їх містить, спосіб профілактики або лікування тромбозу у ссавців (варіанти)
AU7862794A (en) 1993-10-19 1995-05-08 Sumitomo Pharmaceuticals Company, Limited 2,3-diaminopropionic acid derivative
PL331772A1 (en) * 1996-08-21 1999-08-02 Rhone Poulenc Rorer Pharma Stable non-hygroscopic crystalline form of n-[n-n-(4-piperidin-4-yl)-n-ethylglycin] compounds
EA002724B1 (ru) * 1997-10-10 2002-08-29 Авентис Фармасьютикалз Продактс Инк. Способ получения азациклоалкилалканоилпсевдотетрапептидов

Also Published As

Publication number Publication date
US6753409B1 (en) 2004-06-22
PL331772A1 (en) 1999-08-02
EA199900217A1 (ru) 1999-08-26
AU4156397A (en) 1998-03-06
CA2263647A1 (en) 1998-02-26
CN1231659A (zh) 1999-10-13
KR20000068229A (ko) 2000-11-25
US6153588A (en) 2000-11-28
JP4008499B2 (ja) 2007-11-14
CA2263647C (en) 2011-02-15
WO1998007696A1 (en) 1998-02-26
EP0923553A4 (en) 1999-12-08
BR9711340A (pt) 1999-08-17
SK21999A3 (en) 2000-02-14
DE69738601D1 (de) 2008-05-08
AP9901462A0 (en) 1999-03-31
CN1491942A (zh) 2004-04-28
JP2000517305A (ja) 2000-12-26
DE69738601T2 (de) 2009-04-30
IL128561A0 (en) 2000-01-31
EA001362B1 (ru) 2001-02-26
ZA977510B (en) 1998-05-21
ATE390438T1 (de) 2008-04-15
BG63538B1 (bg) 2002-04-30
EP0923553B1 (en) 2008-03-26
NO990721D0 (no) 1999-02-16
BG103225A (en) 2000-01-31
OA10979A (en) 2001-11-01
AU733591B2 (en) 2001-05-17
EP0923553A1 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
NO990721L (no) Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser
NO20032758D0 (no) Krystallinske former av Atorvastatin
NO20075376L (no) Farmasoytisk preparat og dets anvendelse
PT1004578E (pt) Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
NO176519C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske ketoner
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
NZ536734A (en) Spiroindolinepiperidine derivatives
ATE326453T1 (de) Antithrombotische amide
DE69919212D1 (de) Aromatische amiden
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
WO2002010154A3 (en) Substituted heterocyclic amides
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
IL136100A (en) Biphenylamidine derivatives and pharmaceutical compositions containing the same
HUT57773A (en) Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds
NO990836L (no) Antitrombotiske azacykloalkylalkanoylpeptider og pseudopeptider
NO173444C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 4-(4'- fluorfenyl-)-tienopyridin-derivater
ES2154830T3 (es) Derivados de 2-aminolactama n-(4-bencilo sustituida).
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
AP2002002707A0 (en) 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors.
FI944076A7 (fi) Menetelmä terapeuttisesti käytt¦kelpoisten N-(3-hydroksi-4-piperidinyyli)(dihydrobentsofuraani-, dihydro-2H-bentsopyraani- tai dihydrobentsodioksiini)karboksamidijohdannaisten valmistamiseksi ja välituote